TG regulates multiple signaling pathways and inflammatory factors in RA patients, including upregulating alpha7 nicotinic acetylcholine receptor (α7nAChR) expression, inhibiting NF-κB and STAT3 activation, and reducing IL-17 and high mobility group box protein 1 (HMGB1) levels (182).TG tablets (TGTs) combined with MTX significantly improve RA symptoms and immune function by increasing CD3+ and CD4+/CD8+ T lymphocyte levels in RA patients (41, 178, 183). The gene discussed is IL17A; the disease is rheumatoid arthritis.